Does Infliximab Influence Surgical Morbidity of Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis?
- 1 November 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Diseases of the Colon & Rectum
- Vol. 50 (11), 1747-1753
- https://doi.org/10.1007/s10350-007-9008-3
Abstract
Since infliximab has been approved for treatment of patients with refractory ulcerative colitis, surgeons will be increasingly faced with operating on patients who have failed therapy with this potent immunosuppressant. This study was designed to compare short-term complications in patients with ulcerative colitis who were treated with and without infliximab before colectomy. The charts of patients undergoing ileal pouch-anal anastomosis or subtotal colectomy for refractory ulcerative colitis during the five-year period ending October 2005 were reviewed. Postoperative medical and surgical complications were assessed. Seventeen patients had failed infliximab treatment and 134 patients were never treated with infliximab. Ileal pouch-anal anastomosis was performed in 112 patients (74 percent) and subtotal colectomy in 39 patients (36 percent). There were no deaths. Postoperative complications were observed in 43 patients (28 percent), with no significant difference observed between infliximab-treated (37 percent) and infliximab-untreated patients (27 percent). Of 61 patients (40 percent) treated with preoperative cyclosporine A, 5 patients also had been treated with infliximab. The infliximab and cyclosporine A-treated patient group had an 80 percent complication rate, significantly higher than the 29 percent complication rate noted in the cyclosporine A only-treated group (P = 0.04). Although preoperative treatment with infliximab alone does not significantly increase the incidence of postoperative complications, using both inflixiamb and cyclosporine A before colectomy in refractory ulcerative colitis is associated with high surgical morbidity.Keywords
This publication has 17 references indexed in Scilit:
- American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel DiseaseGastroenterology, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005
- Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm CountyGut, 2004
- The risk of post‐operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort studyAlimentary Pharmacology & Therapeutics, 2004
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentThe New England Journal of Medicine, 2001
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseThe New England Journal of Medicine, 1997
- Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporinDiseases of the Colon & Rectum, 1995
- Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide.The Journal of Experimental Medicine, 1990
- Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in VitroScience, 1985